专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08188244B2 Carcinoembryonic antigen fusions and uses thereof 有权
标题翻译：癌胚抗原融合物及其用途
公开(公告)号：US08188244B2
公开(公告)日：2012-05-29
申请号：US10589180
申请日：2005-02-03
申请人： Nicola La Monica , Andrea Facciabene , Luigi Aurisicchio , Gennaro Ciliberto
发明人： Nicola La Monica , Andrea Facciabene , Luigi Aurisicchio , Gennaro Ciliberto
IPC分类号： C12N15/11 , C12N15/63
CPC分类号： C07K14/70503 , A61K2039/53 , C07K2319/30 , C07K2319/55 , Y02A50/472
摘要： Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：提供了编码癌胚抗原（CEA）融合蛋白的多核苷酸，包含CEA蛋白或其功能变体的CEA融合蛋白与免疫增强元件的大部分融合。本发明的多核苷酸可以在哺乳动物中引发免疫应答，在优选的实施方案中，它们比由野生型CEA引起的免疫应答更强。编码CEA的基因通常与人类癌的发展有关。本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。本发明具体提供携带编码CEA融合蛋白的多核苷酸的腺病毒载体和质粒构建体，并公开了其用于预防和治疗癌症的疫苗和药物组合物中。

2. 发明申请

US20080311137A1 Carcinoembryonic Antigen Fusions and Uses Thereof 有权
标题翻译：癌胚抗原融合及其用途
公开(公告)号：US20080311137A1
公开(公告)日：2008-12-18
申请号：US10589180
申请日：2005-02-03
申请人： Nicola La Monica , Andrea Facciabene , Luigi Aurisicchio , Gennaro Ciliberto
发明人： Nicola La Monica , Andrea Facciabene , Luigi Aurisicchio , Gennaro Ciliberto
IPC分类号： A61K39/00 , C07H21/04 , C12N15/63 , C12N5/06 , A61P35/00 , C12P21/02 , C07K19/00
CPC分类号： C07K14/70503 , A61K2039/53 , C07K2319/30 , C07K2319/55 , Y02A50/472
摘要： Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：提供了编码癌胚抗原（CEA）融合蛋白的多核苷酸，包含CEA蛋白或其功能变体的CEA融合蛋白与免疫增强元件的大部分融合。本发明的多核苷酸可以在哺乳动物中引发免疫应答，在优选的实施方案中，它们比由野生型CEA引起的免疫应答更强。编码CEA的基因通常与人类癌的发展有关。本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。本发明具体提供携带编码CEA融合蛋白的多核苷酸的腺病毒载体和质粒构建体，并公开了其用于预防和治疗癌症的疫苗和药物组合物中。

3. 发明授权

US08106176B2 Matrix metalloproteinase 11 vaccine 有权
标题翻译：基质金属蛋白酶11疫苗
公开(公告)号：US08106176B2
公开(公告)日：2012-01-31
申请号：US12083031
申请日：2006-10-03
申请人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
发明人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
IPC分类号： C07H1/00 , C07H5/04 , C07H5/06 , C07H19/00 , C07H21/00 , C07H21/04 , C08B37/00 , C12P21/06 , C12N5/00 , C12N5/02
CPC分类号： C12N9/6416 , A61K39/00 , C07K2319/00 , Y02A50/472
摘要： Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
摘要翻译：描述了包含基质金属蛋白酶11（MMP-11）或基质溶素-3（ST-3）的组合物或编码用于治疗过表达MMP-11的肿瘤和癌症的疫苗中的MMP-11的核酸。在具体实施方案中，组合物包含编码融合多肽的核酸，其包含在C-末端连接至免疫增强元件的催化失活的MMP-11，其中编码MMP-11和免疫增强元件的密码子已被优化以增强表达的人类细胞中的融合多肽。在其它实施方案中，组合物包含在C末端与免疫增强元件连接的催化失活的MMP-11。组合物可以单独使用或与抗其他肿瘤相关抗原的疫苗以及常规疗法如放射治疗和化学疗法协同使用。

4. 发明授权

US08492522B2 Matrix metalloproteinase 11 vaccine 有权
标题翻译：基质金属蛋白酶11疫苗
公开(公告)号：US08492522B2
公开(公告)日：2013-07-23
申请号：US13332580
申请日：2011-12-21
申请人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
发明人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
IPC分类号： C07K1/00 , C07K14/00 , C07K17/00 , G01N33/00
CPC分类号： C12N9/6416 , A61K39/00 , C07K2319/00 , Y02A50/472
摘要： Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
摘要翻译：描述了包含基质金属蛋白酶11（MMP-11）或基质溶素-3（ST-3）的组合物或编码用于治疗过表达MMP-11的肿瘤和癌症的疫苗中的MMP-11的核酸。在具体实施方案中，组合物包含编码融合多肽的核酸，其包含在C-末端连接至免疫增强元件的催化失活的MMP-11，其中编码MMP-11和免疫增强元件的密码子已被优化以增强表达的人类细胞中的融合多肽。在其它实施方案中，组合物包含在C末端与免疫增强元件连接的催化失活的MMP-11。组合物可以单独使用或与抗其他肿瘤相关抗原的疫苗以及常规疗法如放射治疗和化学疗法协同使用。

5. 发明申请

US20090155298A1 Matrix Metalloproteinase 11 Vaccine 有权
标题翻译：基质金属蛋白酶11疫苗
公开(公告)号：US20090155298A1
公开(公告)日：2009-06-18
申请号：US12083031
申请日：2006-10-03
申请人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
发明人： Luigi Aurisicchio , Daniela Peruzzi , Nicola La Monica , Gennaro Ciliberto , Domenico Lazzaro , Federica Mori
IPC分类号： A61K39/00 , C07H21/00 , C12N15/63 , C12N5/10 , C07K14/00 , A61P31/00
CPC分类号： C12N9/6416 , A61K39/00 , C07K2319/00 , Y02A50/472
摘要： Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid en->coding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.
摘要翻译：描述了包含基质金属蛋白酶11（MMP-11）或基质溶素-3（ST-3）或编码用于治疗过表达MMP-11的肿瘤和癌症的疫苗中的MMP-11的核酸的组合物。在具体实施方案中，组合物包含编码融合多肽的核酸，其包含在C-末端连接至免疫增强元件的催化失活的MMP-11，其中编码MMP-11和免疫增强元件的密码子已被优化以增强表达的人类细胞中的融合多肽。在其它实施方案中，组合物包含在C末端与免疫增强元件连接的催化失活的MMP-11。组合物可以单独使用或与抗其他肿瘤相关抗原的疫苗以及常规疗法如放射治疗和化学疗法协同使用。

6. 发明申请

US20110182926A1 MINIGENE 审中-公开
公开(公告)号：US20110182926A1
公开(公告)日：2011-07-28
申请号：US13058304
申请日：2009-08-07
申请人： Nicola La Monica , Elisa Scarselli , Gennaro Ciliberto , Luigi Aurisicchio , Arthur Fridman , Ansuman Bagchi
发明人： Nicola La Monica , Elisa Scarselli , Gennaro Ciliberto , Luigi Aurisicchio , Arthur Fridman , Ansuman Bagchi
IPC分类号： A61K39/00 , C07K19/00 , A61P37/04 , A61P35/00 , A61P31/00
CPC分类号： C07K14/70503 , C07K2319/02 , C07K2319/50 , C07K2319/55 , C12N9/6459
摘要： The present invention provides minigenes suitable as a prophylactic or therapeutic vaccine against conditions such as cancer, infectious diseases or autoimmune diseases, and pharmaceutical compositions comprising the minigene. The minigenes of the present invention comprise (a) a human tissue plasminogen signal peptide; (b) at least one T-cell epitope; and (c) an E. coli heat labile enterotoxin B subunit; wherein the at least one T-cell epitope is linked to the rest of the minigene, and to any other epitopes, by furin sensitive linkers. In some embodiments of the invention, the minigene comprises T-cell epitopes from one or more of CEA, her-2/neu and hTERT. Also provided herein are immunogenic peptide epitopes of CEA, her-2/neu and hTERT, as well as immunogenic peptide analogs, and pharmaceutical compositions and vaccines comprising one or more of said peptides and analogs for prophylaxis and/or treatment of cancer or other disorder. Methods of inducing an immune response in a patient, in addition to methods of treatment using the minigenes, immunogenic peptides, and peptide analogs disclosed herein are also provided.
摘要翻译：本发明提供适合作为针对诸如癌症，感染性疾病或自身免疫性疾病的病症的预防或治疗性疫苗的微创，以及包含小基因的药物组合物。本发明的微生物包含（a）人组织纤溶酶原信号肽; （b）至少一个T细胞表位; 和（c）大肠杆菌热不稳定肠毒素B亚基; 其中所述至少一个T细胞表位与所述小基因的其余部分和通过弗林蛋白酶敏感性接头连接到任何其它表位。在本发明的一些实施方案中，小基因包含来自CEA，her-2 / neu和hTERT中的一种或多种的T细胞表位。本文还提供了CEA，her-2 / neu和hTERT的免疫原性肽表位以及免疫原性肽类似物，以及包含一种或多种所述肽和类似物用于预防和/或治疗癌症或其它疾病的药物组合物和疫苗。还提供了在使用本文公开的微生物，免疫原性肽和肽类似物的治疗方法之外，在患者体内诱导免疫应答的方法。

7. 发明申请

US20060286114A1 Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof 审中-公开
标题翻译：编码恒河猴癌胚抗原的合成基因及其用途
公开(公告)号：US20060286114A1
公开(公告)日：2006-12-21
申请号：US10568168
申请日：2004-08-17
申请人： Luigi Aurisicchio , Nicola La Monica , Patrizia Giannetti , Gennaro Ciliberto
发明人： Luigi Aurisicchio , Nicola La Monica , Patrizia Giannetti , Gennaro Ciliberto
IPC分类号： A61K39/00 , C07H21/04 , C12P21/06 , C12N5/06 , C07K14/82 , A61K48/00
CPC分类号： C12N15/86 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0331 , A61K39/00 , A61K2039/53 , C07K14/4748 , C12N15/8509 , C12N2710/10343
摘要： Synthetic polynucleotides encoding rhesus monkey carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being condon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenovial vector and plasmid constructs carrying codon-optimed rhesus monkey CEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：提供了编码恒河猴癌胚抗原（CEA）的合成多核苷酸，对人类细胞环境中的表达进行了宽带优化的合成多核苷酸。编码CEA的基因通常与人类癌的发展有关。本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。本发明具体提供携带密码子优化的恒河猴CEA的腺病毒载体和质粒构建体，并公开了它们在预防和治疗癌症的疫苗和药物组合物中的用途。

8. 发明申请

US20060228335A1 Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof 审中-公开
标题翻译：恒河猴胚胎胚胎抗原，编码其的核苷酸及其用途
公开(公告)号：US20060228335A1
公开(公告)日：2006-10-12
申请号：US10545515
申请日：2004-02-09
申请人： Luigi Aurisicchio , Fabio Palombo , Paolo Monaci , Nicola La Monica , Gennaro Ciliberto , Armin Lahm
发明人： Luigi Aurisicchio , Fabio Palombo , Paolo Monaci , Nicola La Monica , Gennaro Ciliberto , Armin Lahm
IPC分类号： A61K48/00 , C07H21/04 , C12P21/06 , C07K14/82 , C12N5/06
CPC分类号： A61K39/0011 , A61K38/00 , A61K2039/5256 , A61K2039/53 , C07K14/70503 , C07K16/3007
摘要： DNAs encoding rhesus monkey carcinoembryonic antigen (rhCEA) have been isolated, cloned and sequenced. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhCEA and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.
摘要翻译：已经分离，克隆和测序编码恒河猴癌胚抗原（rhCEA）的DNA。编码CEA的基因通常与人类癌的发展有关。本发明提供了引发或增强由CEA肿瘤相关抗原表达的蛋白质产物的免疫的组合物和方法，其中异常CEA表达与癌症或其发展相关。本发明具体提供携带rhCEA的腺病毒载体构建体，并公开了它们在预防和治疗癌症的疫苗和药物组合物中的用途。

9. 发明授权

US09688738B2 Immunotherapy against ErbB-3 receptor 有权
公开(公告)号：US09688738B2
公开(公告)日：2017-06-27
申请号：US13882899
申请日：2011-11-02
申请人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
发明人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
IPC分类号： A61K39/395 , C07K16/30 , C07K14/705 , A61K38/17 , A61K39/00 , C07K14/71 , C07K16/32 , A61K45/06 , A61K31/7088
CPC分类号： C07K14/705 , A61K31/7088 , A61K38/179 , A61K39/0011 , A61K45/06 , A61K2039/507 , A61K2039/53 , C07K14/71 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.

10. 发明申请

US20140017259A1 IMMUNOTHERAPY AGAINST ERBB-3 RECEPTOR 有权
标题翻译：对ERBB-3受体的免疫治疗
公开(公告)号：US20140017259A1
公开(公告)日：2014-01-16
申请号：US13882899
申请日：2011-11-02
申请人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
发明人： Luigi Aurisicchio , Gennaro Ciliberto , Rita Mancini , Emanuele Marra , Guiseppe Roscilli
IPC分类号： C07K14/705
CPC分类号： C07K14/705 , A61K31/7088 , A61K38/179 , A61K39/0011 , A61K45/06 , A61K2039/507 , A61K2039/53 , C07K14/71 , C07K16/32 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/76 , A61K2300/00
摘要： The present invention describes methods and pharmaceutical compositions for the treatment of cancer in mammals, more particularly in human subjects. More specifically, the invention concerns anti-tumor vaccines based upon plasmid DNA and/or genetic vectors carrying a codon-usage optimized sequence and coding for a mutant form of the ErbB-3 receptor. Furthermore, the invention refers to monoclonal antibodies directed against the ErbB-3 receptor, obtained using these methods and capable to block its activity in cancer cells.
摘要翻译：本发明描述了用于治疗哺乳动物癌症的方法和药物组合物，更特别在人类受试者中。更具体地，本发明涉及基于携带密码子使用优化序列并编码ErbB-3受体的突变体形式的质粒DNA和/或遗传载体的抗肿瘤疫苗。此外，本发明涉及使用这些方法获得的能够阻断其在癌细胞中的活性的针对ErbB-3受体的单克隆抗体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式